The DNMT3B Inhibitor Nanaomycin A as a Neuroblastoma Therapeutic Agent.
Curr Cancer Drug Targets
; 23(11): 837-842, 2023.
Article
em En
| MEDLINE
| ID: mdl-37221685
ABSTRACT
BACKGROUND:
Neuroblastoma is one of the most common childhood solid tumors. Because tumor suppressor genes are often hypermethylated in cancers, DNA methylation has emerged as a target for cancer therapeutics. Nanaomycin A, an inhibitor of DNA methyltransferase 3B, which mediates de novo DNA methylation, reportedly induces death in several types of human cancer cells.OBJECTIVE:
To study the antitumor activity of nanaomycin A against neuroblastoma cell lines and its mechanism.METHODS:
The anti-tumor effect of nanaomycin A on neuroblastoma cell lines was evaluated based on cell viability, DNA methylation levels, apoptosis-related protein expression, and neuronal-associated mRNA expression.RESULTS:
Nanaomycin A decreased genomic DNA methylation levels and induced apoptosis in human neuroblastoma cells. Nanaomycin A also upregulated the expression of mRNAs for several genes related to neuronal maturation.CONCLUSIONS:
Nanaomycin A is an effective therapeutic candidate for treating neuroblastoma. Our findings also suggest that the inhibition of DNA methylation is a promising anti-tumor therapy strategy for neuroblastoma.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Naftoquinonas
/
Neuroblastoma
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article